Buy Rating on Context Therapeutics's CTIM-76 Bolstered by Market Validation and Competitive Edge
TipRanksApr 12 01:15
Buy Rating Justified by Advances in T Cell Engagers and Context Therapeutics' Strategic Drug Positioning
TipRanksMar 23 01:55
Context Therapeutics' Promising Financial and Preclinical Results Bolster Buy Rating: A Focus on CTIM-76's High Potency and Target Specificity
TipRanksNov 11, 2023 20:06
Promising Potential of CTIM-76 Drug: A Comprehensive Buy Rating Analysis for Context Therapeutics
TipRanksNov 10, 2023 19:47
HC Wainwright & Co. Upgrades Context Therapeutics to Buy, Announces $5 Price Target
BenzingaNov 1, 2023 19:17
Context Therapeutics Analyst Ratings
BenzingaNov 1, 2023 19:16
Analysts Are Bullish on These Healthcare Stocks: AstraZeneca (AZN), Context Therapeutics (CNTX)
TipRanksOct 25, 2023 03:10
H.C. Wainwright Remains a Hold on Context Therapeutics (CNTX)
TipRanksOct 24, 2023 18:18
Context Therapeutics' Promising CLDN6 Targeting Asset CTIM-76 and Potential Market Valuation Opportunities: An Analyst's Buy Rating Perspective
TipRanksSep 29, 2023 02:26
Context Therapeutics Analyst Ratings
BenzingaSep 11, 2023 20:24
H.C. Wainwright Downgrades Context Therapeutics (CNTX) to a Hold
TipRanksMar 23, 2023 18:21
Context Therapeutics Analyst Ratings
Benzinga Analyst RatingsFeb 7, 2023 19:25
HC Wainwright & Co. Reiterates Buy on Context Therapeutics, Maintains $4 Price Target
Benzinga Real-time NewsFeb 7, 2023 19:25
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Context Therapeutics (CNTX)
TipRanksFeb 7, 2023 19:21
H.C. Wainwright Sticks to Their Buy Rating for Context Therapeutics (CNTX)
TipRanksDec 9, 2022 02:05
Context Therapeutics (CNTX) Receives a Buy From H.C. Wainwright
TipRanksDec 2, 2022 20:05
H.C. Wainwright Remains a Buy on Context Therapeutics (CNTX)
TipRanksNov 10, 2022 19:35
No Data
No Data